Biocon now owns an 85.54 percent stake in Syngene
Biotechnology major Biocon could file a prospectus for a share listing for its research services business arm Syngene International within the next two months, says reports.
Earlier this year, Biocon has said that it is looking to sell 10-15 percent stock from its majority stake in Syngene via an offer for sale. The company now owns an 85.54 percent stake in Syngene.
Reportedly, The IPO for Syngene will be managed by Credit Suisse, Axis Bank and Jefferies.